or Try an Advanced Search...

    Technical Analysis for MORF - Morphic Holding, Inc.

    Grade Last Price % Change Price Change
    A 56.99 0.04% 0.02
    MORF closed up 0.04 percent on Thursday, August 15, 2024, on 61 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Flat
    Historical MORF trend table...
    Date Alert Name Type % Chg
    Gilligan's Island Sell Setup Bearish Swing Setup 2.24%
    Pocket Pivot Bullish Swing Setup 2.24%
    Volume Surge Other 2.24%
    NR7 Range Contraction 2.24%
    NR7-2 Range Contraction 2.24%
    Narrow Range Bar Range Contraction 2.24%
    Parabolic Rise Strength 2.24%
    Wide Bands Range Expansion 2.24%
    Above Upper BB Strength 2.24%
    Gapped Up Strength 2.24%
    Older End-of-Day Signals for MORF ...

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MORF Chart by TradingView
    Basic chart:

    Profile

    Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Gastrointestinal Cancer Treatment Of Inflammatory Bowel Disease Integrin

    Is MORF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Aug 19 Eli Lilly acquires Morphic in IBD portfolio expansion
    Aug 16 Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
    Aug 12 Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal
    Aug 12 Eli Lilly Sells $5 Billion of Bonds to Fund Morphic Deal
    Aug 1 Q2 2024 Schrodinger Inc Earnings Call
    Aug 1 Morphic Holding ticks higher after HSR waiting period for Eli Lilly deal expires
    Jul 19 Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
    Jul 12 Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
    Jul 9 Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
    Jul 9 Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
    See more MORF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 57.0
    52 Week Low 19.345
    Average Volume 2,937,396
    200-Day Moving Average 33.75
    50-Day Moving Average 45.49
    20-Day Moving Average 56.76
    10-Day Moving Average 56.91
    Average True Range 0.52
    RSI (14) 83.44
    ADX 70.74
    +DI 59.08
    -DI 7.71
    Chandelier Exit (Long, 3 ATRs) 55.44
    Chandelier Exit (Short, 3 ATRs) 57.53
    Upper Bollinger Bands 57.09
    Lower Bollinger Band 56.44
    Percent B (%b) 0.85
    BandWidth 1.15
    MACD Line 2.73
    MACD Signal Line 3.58
    MACD Histogram -0.8441
    Fundamentals Value
    Market Cap 2.83 Billion
    Num Shares 49.7 Million
    EPS -3.29
    Price-to-Earnings (P/E) Ratio -17.32
    Price-to-Sales 296.69
    Price-to-Book 2.73
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 57.04
    Resistance 3 (R3) 57.03 57.02 57.03
    Resistance 2 (R2) 57.02 57.01 57.02 57.02
    Resistance 1 (R1) 57.00 57.00 57.01 57.01 57.02
    Pivot Point 56.99 56.99 56.99 56.99 56.99
    Support 1 (S1) 56.97 56.98 56.98 56.98 56.96
    Support 2 (S2) 56.96 56.97 56.96 56.96
    Support 3 (S3) 56.94 56.96 56.95
    Support 4 (S4) 56.95